Abstract:Emerging evidence suggests that the APOBEC family is implicated in multiple cancers and might be utilized as a new target for cancer detection and treatment. However, the dysregulation and clinical implication of the APOBEC family in clear cell renal cell cancer (ccRCC) remain elusive. TCGA multiomics data facilitated a comprehensive exploration of the APOBEC family across cancers, including ccRCC. Remodeling analysis classified ccRCC patients into two distinct subgroups: APOBEC family pattern cancer subtype 1 (APCS1) and subtype 2 (APCS2). The study investigated differences in clinical parameters, tumor immune microenvironment, therapeutic responsiveness, and genomic mutation landscapes between these subtypes. An APOBEC family-related risk model was developed and validated for predicting ccRCC patient prognosis, demonstrating good sensitivity and specificity. Finally, the overview of APOBEC3B function was investigated in multiple cancers and verified in clinical samples. APCS1 and APCS2 demonstrated considerably distinct clinical features and biological processes in ccRCC. APCS1, an aggressive subtype, has advanced clinical stage and a poor prognosis. APCS1 exhibited an oncogenic and metabolically active phenotype. APCS1 also exhibited a greater tumor mutation load and immunocompromised condition, resulting in immunological dysfunction and immune checkpoint treatment resistance. The genomic copy number variation of APCS1, including arm gain and loss, was much more than that of APCS2, which may help explain the tired immune system. Furthermore, the two subtypes have distinct drug sensitivity patterns in clinical specimens and matching cell lines. Finally, we developed a predictive risk model based on subtype biomarkers that performed well for ccRCC patients and validated the clinical impact of APOBEC3B. Aberrant APOBEC family expression patterns might modify the tumor immune microenvironment by increasing the genome mutation frequency, thus inducing an immune-exhausted phenotype. APOBEC family-based molecular subtypes could strengthen the understanding of ccRCC characterization and guide clinical treatment. Targeting APOBEC3B may be regarded as a new therapeutic target for ccRCC.

APOBEC3 as a driver of genetic intratumor heterogeneity

Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution

Data from Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution

APOBEC3 mutational signatures are associated with extensive and diverse genomic instability across multiple tumour types

Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases

APOBEC3 genes: retroviral restriction factors to cancer drivers

Evolvability of cancer-associated genes under APOBEC3A/B selection

Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types

APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential

The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance

APOBEC Alteration Contributes to Tumor Growth and Immune Escape in Pan-Cancer

Regulation, functional impact, and therapeutic targeting of APOBEC3A in cancer

Multiple roles of apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) in human tumors: a pan-cancer analysis

The centraI roIe of APOBEC3B in cancer deveIopment

Differentiation signals induce APOBEC3A expression via GRHL3 in squamous epithelia and squamous cell carcinoma

The interesting relationship between APOBEC3 deoxycytidine deaminases and cancer: a long road ahead

Abstract P5-13-05: Profiling of APOBEC3 dysregulation in breast cancer

APOBEC3A is a prominent cytidine deaminase in breast cancer

APOBEC family reshapes the immune microenvironment and therapy sensitivity in clear cell renal cell carcinoma

Upregulation of the APOBEC3 Family is Associated with a Poor Prognosis and Influences Treatment Response to Raf Inhibitors in Low Grade Glioma